Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Greg22 who wrote (22520)	9/26/1999 11:09:00 PM
From: E_K_S	Read Replies (1) \| Respond to of 23519

Hi Gregg22 - I believe VVUS recently signed an agreement with AstraZeneca (AstraZeneca to Pay $2 Million Milestone biz.yahoo.com to market MUSE in Spain. I also believe we will hear some news regarding a VIVUS distribution agreement in Italy. As far as VVUS's earnings, I am guessing that they will be very good next quarter. One posters on the Raging Bull Site estimated earnings expectations for VVUS next quarter at $0.09 and $0.40 for the year! (http://www.ragingbull.com/mboard/boards.cgi?board=VVUS&read=3957) At 50 times earnings, I guess you be looking for a buy out at $20.00 per share. I would agree to a $10.00/share but out BUT in Abbott stock. Also I would expect a 20% premium, or an additional $ 2.00/share. At current prices VVUS is a steal at $3.00/share! IMO, ABBOTT would make an excellent partner as long as a fair value plus a 20% premium is paid to current share holders (ie. $12.00/share). Do you think the shorts would begin to cover on such news? EKS